Canaccord Genuity Sees Bristol-Myers Acquiring Control of bb2121 from bluebird bio (BLUE)

January 24, 2019 10:32 AM
Canaccord Genuity analyst John Newman expects Bristol-Myers (NYSE: BMY) to acquire 100% control of bb2121 from bluebird bio (NASDAQ: BLUE) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


Analyst Comments Hot Comments Mergers and Acquisitions Rumors Trader Talk

Next Articles